Registration
 
All news
Top Stories
Editors' Picks
Stocks
Crypto
Economics
Currencies
Commodities
Business & Wealth
Market Voices
Anastasiia Chabaniuk
Anastasiia Chabaniuk

AbbVie stock holds steady as Q3 2026 financial results investor call

AbbVie stock holds steady as Q3 2026 financial results investor call
AbbVie stock is little changed today

AbbVie announced plans for an investor call on October 30 to discuss its third-quarter 2026 results. Shares are little changed on the day, trading near $286.44.

ABBV price prediction
24H -0.33%
$292.91
48H -0.15%
$293.44
7D -0.04%
$293.75
1M 5.69%
$310.59
3M 14.24%
$335.72
6M 7.1%
$314.74
12M 29.5%
$380.56
Detailed
Current price: $293.87 0.5700 0.19%
Closed 11/10
Daily range 291.04 Arrow from to Icon 294.49
Weekly range 281.96 Arrow from to Icon 302.68
Loading...

Highlights

  • AbbVie will hold an investor call on October 30 to present its third-quarter 2026 financial results.
  • Analysts expect AbbVie to report diluted EPS of $3.76 for Q3 2026, a 102.2% increase over the prior year.
  • Shares of AbbVie are little changed today, trading near $286.44 with a market value close to $488.55 billion.

AbbVie announced on October 15, 2026 that it would hold an investor call on October 30 to share its Q3 2026 financial results. Analysts expect the company to report diluted EPS of $3.76 for the quarter, an increase of 102.2% from a year earlier, according to Yahoo! Finance. The company has exceeded consensus estimates in each of the last four quarters, Yahoo! Finance reported.

Bullish structure holds as price recovers from early gap down

AbbVie stock opened the session with a gap down from $286.74 to $283.88, and has since retraced part of that decline. The price is holding above its MA-20, MA-50 and MA-200, which keeps the daily structure bullish for now. With RSI at 65 nearing overbought territory, the ongoing advance could be getting stretched, and the nearest resistance sits at the weekly high of $289.59.

Upside odds remain high as traders watch the weekly high

Traders should watch for a close above $289.59 to gauge whether the revenue news is being fully priced in. The session began with a gap down from $286.74 to $283.88 before partially recovering. From here, the probability of upside over the next five trading days is more than 80%, while downside risk sits at less than 20%; AbbVie shares are expected to trade in a $281.6 to $291.27 range. Still, a close above the weekly high would show buyers are willing to follow through, while a drop below $278.78 would indicate the move is being faded. On the weekly chart, the longer-term picture stays firmly constructive.

Earlier, analysts noted that AbbVie's sustained technical momentum and recent regulatory approvals were supporting a bullish outlook for the stock. The upcoming earnings release now adds a critical catalyst, with the path forward likely to hinge on whether shares can decisively clear the $289.59 resistance in the wake of new financial results.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.

Editor's Picks for You

Tom Lee’s Ethereum bet: Why he expects another crypto boom
  • By Mikhail Vnuchkov
  • 9 hours ago
Tom Lee’s Ethereum bet: Why he expects another crypto boom
Editors' Picks
How Paul McCartney became a billionaire and the role the stock market played
  • By Eugene Komchuk
  • 12 hours ago
How Paul McCartney became a billionaire and the role the stock market played
Editors' Picks
Buterin’s new vision: Why Ethereum wants to become digital gold
  • By Olena Litvinenko
  • Yesterday
Buterin’s new vision: Why Ethereum wants to become digital gold
Editors' Picks
All Editors' Top Picks

Latest AbbVie News

AbbVie stock weekly forecast: MACD and ADX support further upside as momentum trends higher
  • By Yaroslav Dmytrenko
  • 03.11.2026
AbbVie stock weekly forecast: MACD and ADX support further upside as momentum trends higher
Stocks
#Forecast #AbbVie
AbbVie shares drop almost 2% after strong Q3 results and raised dividend
  • By Hlib Chabaniuk
  • 02.11.2026
AbbVie shares drop almost 2% after strong Q3 results and raised dividend
Stocks
#Forecast #AbbVie
AbbVie shares Q3 2026 financial results after stock ends session up 1.7%
  • By Yaroslav Dmytrenko
  • 30.10.2026
AbbVie shares Q3 2026 financial results after stock ends session up 1.7%
Companies
#AbbVie
All AbbVie News
  • Mikhail Vnuchkov
  • 9 hours ago
Tom Lee’s Ethereum bet: Why he expects another crypto boom
  • Eugene Komchuk
  • 12 hours ago
How Paul McCartney became a billionaire and the role the stock market played
  • Olena Litvinenko
  • Yesterday
Buterin’s new vision: Why Ethereum wants to become digital gold
  • Anastasiia Chabaniuk
  • Yesterday
From affair to market crash: How the Nvidia scandal hit Bitcoin
  • Dmytro Kharkov
  • Yesterday
Shield AI’s Echodyne deal and the global counter-drone race
  • Hanna Syniavska
  • 9 min ago
Gram outperforms as crypto falls, Pavel Durov notes
  • Mikhail Vnuchkov
  • 14 min ago
NVDA faces key support at $155 and a put wall at $150, Lia Holmgren notes
  • Eugene Komchuk
  • 14 min ago
Deirdre Bosa: OpenAI Q3 revenue reaches $10 billion, nearly 50 percent increase from prior quarter
  • Elena Nikulina
  • 14 min ago
Many buy Nvidia after 30 percent drop, David Bird notes
  • Pavlo Kot
  • 24 min ago
Reflecting on portfolio downturns is important, Michael van de Poppe notes
Top News
  • Ivan Andriyenko
  • 6 hours ago
U.S. core inflation beats forecasts for third consecutive month
U.S. core inflation beats forecasts for third consecutive month
  • Eugene Komchuk
  • 6 hours ago
Public companies have sold $8 billion in Bitcoin so far in 2026
Public companies have sold $8 billion in Bitcoin so far in 2026
  • Andrey Mastykin
  • 7 hours ago
Oil prices tumble as fears of Iran escalation fade
Oil prices tumble as fears of Iran escalation fade
  • Hanna Syniavska
  • 8 hours ago
U.S. stock futures trade mixed ahead of crucial inflation report
U.S. stock futures trade mixed ahead of crucial inflation report
  • Igor Krasulya
  • 10 hours ago
Fed Governor Waller warns inflation could justify 50-basis-point rate hike
Fed Governor Waller warns inflation could justify 50-basis-point rate hike
Live News
  • Kyle Torpey
  • Now
Binance hackers launder stolen funds through Elon Musk-themed memecoins
  • Mykhailo Ihnatenko
  • Now
Intel stock forecast: Can CPI volatility derail the rebound toward 70?
  • Jose Antonio Gastelum
  • Now
Polymarket widens lead over Kalshi in political prediction markets
  • Anton Kharitonov
  • Now
EUR/USD holds above 1.1200 as traders await U.S. inflation data
  • Eugene Komchuk
  • Now
BitGo revenue halves amid crypto trading slowdown
Who We Are
Business Solutions
For Users
TU News
Popular Sections
Disclosures
CONTACT US
Legal
We are in Social Media
© IAFT Ltd., 2010-2026 All rights to the website are owned by IAFT Ltd.,
Registration number - HE 336186
  • Risk disclosure:

    Information on the TradersUnion.com website is for informational purposes only and does not constitute any motive or suggestion to visitors to invest money. Moreover, we hereby warn you that trading on the Forex and CFD markets is always a high risk. According to the statistics, 75-89% of customers lose the funds invested and only 11-25% of traders earn a profit. Trading in futures and options carries substantial risk of loss and is not suitable for every investor.

    That is why you should only invest money that you are prepared — or can afford — to lose at such high risks. Tradersunion.com does not provide any financial services, including investment or financial advisory services. Also, the Traders Union is not a broker and does not get money for trading in the Forex or CFD markets. Our website only provides information on brokers and the markets and helps its users to select the best brokerage company based on detailed information and objective analysis of brokers.

  • Disclaimer:

    Traders Union (TradersUnion.com) shall not be liable for the consequences of trading decisions made by the Client and for the possible loss of his capital resulting from the use of this website and information published on it.

    Forex market, CFD and cryptocurrency trading involves high risks and is not suitable for everyone. Before investing money, you need to adequately assess the level of your expertise and be aware of the risks, particularly in the context of trading with leverage. The information on this website is not intended for distribution or use by any person in any country or jurisdiction, where such distribution or use would be in violation of the local law or regulation. Any payments by Traders Union (TradersUnion.com) to the users of our website shall be legally interpreted solely as an incentive on our part for the activity on the website in the form of a deduction of a part of the advertising income; they shall not be a subject of any claims of our users or our obligations, a subject of disputes, as well as cannot be considered in relation to the services provided to users by brokers, both in fact and in their completeness and volume. The administration of the website shall not be liable for the content of user comments and reviews about the companies and shall not verify whether the authors of the reviews are indeed real clients of a specific company. All reviews, both negative and positive are published on the website without verification of their reliability; only offensive reviews that call for violence or any kind of discrimination and also reviews published from one group of IP addresses are moderated and removed. The authors of the materials shall be fully liable for the accuracy, completeness and impartiality of any information in the articles and reviews, including in the context of their use or mention of any brand names or trademarks. All mentions of the names of companies and their brands in any materials on the website shall be made in the context of communication of socially important information to the people about their activities by independent journalists, who are the authors. All evaluations and indicators on the website express the subjective opinion of the authors of the reviews (articles) and shall not be viewed as accurate statements and be a subject of disputes and claims against Traders Union.

  • Disclosure of advertisers and revenues:

    All the services on the Tradersunion.com website are free for you to use. Our team spends thousands of hours per annum researching brokers and gathering information about them to help investors all over the world to choose reliable companies and to avoid fraudsters.

    Indeed, the curating, sourcing, and organization of this process requires substantial financial investment by Tradersunion.com, which the website earns in the form of advertising payments. There are two types of advertising services on the website — direct advertising or partner (broker) participation programs. However, no services purchased by our partners shall affect the recommendations on our website, or our opinions, or ratings. Our ratings are based on our objective rating criteria and methodology; and the results are always equally and fairly applied to each broker. The work of our content authors and research groups does not involve any interaction with our advertisers and they do not have access to data concerning the amount of advertising purchased. For over 10 years we consider our independence, absolute openness, and objectivity as our main priority. Please follow the links to each of our affiliated broker’s websites. This will help Tradersunion.com to continue to provide our services to you for free.

onepercentfortheplanet.org https://gdpr.eu/ GDPR World Association of News Publishers